PubHawk
July 2016 PMID 27295427

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn, William M Steinberg, Mette Stockner, Bernard Zinman, Richard M Bergenstal, John B Buse

Full text PDF Download social card

Mentions

207
Peak: 1 in Apr 2020
across 5 sources since Apr 2020

Extended reach

93,761
potential audience

Total likes

2,222

Video views

93,762

Mentions per month

Apr 2020 – Nov 2025

Where it's discussed

  • News140 articles
  • Facebook46 posts
  • Blogs17 articles
  • YouTube3 videos
  • Bluesky1 posts

AI synopsis

What people are saying

The discussions reflect general support and interest in liraglutide’s benefits, with posts stating phrases like 'life-changing' and 'important breakthrough', highlighting broad enthusiasm and perceived impact. The tone remains accessible, focusing on clinical implications rather than technical data, which suggests moderate engagement without deep technical analysis.

AgreementModerate agreement

Most discussions expressed support for the study’s findings, recognizing the benefits of liraglutide in reducing cardiovascular risks.

InterestModerate interest

The posts showed moderate interest, often commenting on the clinical relevance and safety concerns but not diving deeply into technical details.

EngagementModerate engagement

Users engaged by sharing personal opinions and discussing implications, but few provided detailed analyses or critique.

ImpactNeutral impact

While some acknowledged the significance of the findings for treatment approaches, few posts indicated a broad societal or policy impact.

Abstract in brief

  • Liraglutide, when added to standard care, significantly reduces the risk of major cardiovascular events and death from cardiovascular causes in patients with type 2 diabetes at high risk.
  • The study found that fewer patients in the liraglutide group experienced primary cardiovascular outcomes and died from any cause compared to the placebo group, indicating its potential cardiovascular benefits.
  • The most common side effects leading to stopping liraglutide were gastrointestinal issues, and there was no significant difference in pancreatitis rates between the groups.
Read the full abstract

Top posts

Most liked on X and Bluesky
Joel Topf
@kidneyboy.bsky.social · Bluesky

And LEADER https://www.nejm.org/doi/full/10.1056/nejmoa1603827

Oct 12, 2023 View post →

All mentions

Understanding GLP-1 Medications for Type 2 Diabetes

Ever wonder about medications like Trulicity, Ozempic, or Victoza? This video discusses the role of GLP-1 in managing blood glucose levels, how these medications function, their benefits, and potential side effects…

Sugar High · Apr 30, 2020 93,306 views
Joel Topf
@kidneyboy.bsky.social · Bluesky

And LEADER https://www.nejm.org/doi/full/10.1056/nejmoa1603827

Oct 12, 2023 View post →